Seeking Alpha

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...
Seeking Alpha

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of ...

Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab ...
STAT

A new trick for old science, and biotech VCs’ scrambled playbook

Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA?
Nasdaq

Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance

(RTTNews) - Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting strong gains on the back of corporate ...